Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening

Current Opinion in Chemical Biology

Volumn 12, Issue 3, 2008, Pages 340-351

  Rishton, Gilbert M ^a  

^a CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMPHETAMINE; CARBOHYDRATE; DEXFENFLURAMINE; GALANTAMINE; MORPHINE; PEPTIDE; PHENTERMINE; PROTEIN; SEROTONIN;

ASSAY; ATOM; BIOCHEMICAL SCREENING; CHEMICAL STRUCTURE; CONFORMATION; CRYSTALLIZATION; DRUG SCREENING; LIGAND BINDING; MOLECULAR WEIGHT; PHARMACOPHORE; REACTION ANALYSIS; REVIEW; STRUCTURE ANALYSIS;

BIOLOGICAL PRODUCTS; DRUG EVALUATION, PRECLINICAL; MOLECULAR CONFORMATION; NITROGEN; PHARMACEUTICAL PREPARATIONS; PROTEINS;

ANIMALIA;

EID: 49949151887     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2008.02.008     Document Type: Review

References (49)

1. Lipinski C.A., Lombardo F., Dominy B., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23 (1997) 3-25. Basically set the stage for most of the druglikeness discussions that have followed since its publication.
2. Veber D.F., Johnson S.R., Cheng H., Smith B.R., Ward K.W., and Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45 (2002) 2615-2623. Important recognition that free rotatable bonds are one key to oral bioavailability.
3. Rishton G.M., LaBonte K., Williams A.J., Kassam K., and Kolovanov E. Computational approaches to the prediction of blood-brain barrier permeability: a comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr Opin Drug Discov Drug Dev 9 (2006) 303-313
4. Hitchcock S.A., and Pennington L.D. Structure-brain exposure relationships. J Med Chem 26 (2006) 7559-7583
5. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov Today 2 (1997) 382-384. Identifies protein-reactive functional groups as covalent-acting false positives in biochemical assays and also characterizes the artifact structure-reactivity relationship often observed with these reactives.
6. Rishton G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today 8 (2003) 86-96. Summary review of artifact-generating agents in biochemical screening and an introductory summary of leadlikeness properties.
7. Roche O., Schneider P., Zuegge J., Guba W., Kansy M., Alanine A., Bleicher K., Danel F., Gutknecht E.M., Rogers-Evans M., et al. Development of a virtual screening method for identification of 'Frequent Hitters' in compound libraries. J Med Chem 45 (2002) 137-142
8. McGovern S.L., Helfand B.T., Feng B., and Shoichet B.K. A specific mechanism of nonspecific inhibition. J Med Chem 46 (2003) 4265-4272. Summary of compound classes prone to aggregation and artifact data generation across multiple assays and featuring physical methods to detect aggregates.
9. Seidler J., McGovern S.L., Doman T.N., and Shoichet B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 46 (2003) 4477-4486. Important demonstration that druglike compounds and even known drugs can aggregate in biochemical assays and result in artifact data.
10. McGovern S.L., and Shoichet B.K. Kinase inhibitors: not just for kinases anymore. J Med Chem 46 (2003) 1478-1483
11. Feng B.Y., and Shoichet B.K. Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem 49 (2006) 2151-2154
12. Shoichet B.K. Screening in a spirit haunted world. Drug Discov Today 11 (2006) 607-615
13. Feng B.Y., Simeonov A., Jadhav A., Babaoglu K., Inglese J., Shoichet B.K., and Austin C.P. A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem 50 (2007) 2385-2390
14. Verheij H.J. Leadlikeness and structural diversity of synthetic screening libraries. Mol Divers 10 (2006) 377-388. A rigorous computational analysis of the properties of compounds in the globally available screening collections in the context of leadlikeness.
15. Monge A., Arrault A., Marot C., and Morin-Allory L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol Divers 10 (2006) 389-403
16. Huth J.R., Mendoza R., Olejniczak E.T., Johnson R.W., Cothron D.A., Liu Y., Lerner C.G., Chen J., and Hajduk P.J. ALARM NMR: A rapid and robust experimental method to detect reactive false positives in biochemical screens. J Am Chem Soc 127 (2005) 217-224. Important development of a spectroscopic method to detect protein-reactive false positives.
17. Oprea T.I., Davis A.M., Teague S.J., and Leeson P.D. Is there a difference between leads and drugs? A historical perspective. J Chem Inform Comp Sci 41 (2001) 1308-1315. Seminal paper which suggests physiochemical properties of leads are significantly different than those properties of compounds considered to be druglike.
18. Hann M.M., and Oprea T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 8 (2004) 255-263. Further development of the leadlikeness concept and the physiochemical properties underpinning it.
19. Teague S.J., Davis A.M., Leeson P.D., and Oprea T.I. The design of leadlike combinatorial libraries. Angew Chem Int Ed 38 (1999) 3743-3748
20. Huryn D.M., and Cosford N.D.P. The molecular libraries screening center network (MLSCN): Identifying chemical probes of biological systems. Ann Rep Med Chem 42 (2007) 401-416
21. Austin C.P., Brady L.S., Insel T.R., and Collins F.S. Policy forum: molecular biology: NIH molecular libraries initiative. Science 306 5699 (2004) 1138-1139
22. Lazo J.S. Roadmap or roadkill: A pharmacologist's analysis of the NIH molecular libraries initiative. Mol Interv 6 (2006) 240-243
23. Oprea T.I., Allu Tharun K., Fara D.C., Rad R.F., Ostopovici L., and Bologa C.G. Lead-like, drug-like or 'Pub-like': how different are they?. J Comput Aided Mol Des 21 (2007) 113-119
24. Wyss D.F., and Eaton H.L. Fragment-based approaches to lead discovery. Front Drug Des Discov 3 (2007) 171-202
25. Bartoli S., Fincham C.I., and Fattori D. Fragment-based drug design: combining philosophy with technology. Curr Opin Drug Discov Dev 10 (2007) 422-429
26. Hajduk P.J., and Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6 (2007) 211-219
27. Shuker S.B., Hajduk P.J., Meadows R.P., and Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274 5292 (1996) 1531-1534. Introduction of fragment-based screening concept and spectroscopic assay development.
28. Hajduk P.J., Huth J.R., and Sun C. SAR by NMR: an analysis of potency gains realized through fragment-linking and fragment-elaboration strategies for lead generation. Methods Princ Med Chem 34 (2006) 181-192
29. Jacoby E., Davies J., and Blommers M.J.J. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr Top Med Chem 3 (2003) 11-23
30. Hann M.M., Leach A.R., and Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inform Comput Sci 41 (2001) 856-864
31. Hann M.M., Leach A.R., Burrows J.N., and Griffen E. Lead discovery and the concepts of complexity and lead-likeness in the evolution of drug candidates. Compr Med Chem II 4 (2006) 435-458
32. Schuffenhauer A., Ruedisser S., Marzinzik A.L., Jahnke W., Blommers M., Selzer P., and Jacoby E. Library design for fragment based screening. Curr Top Med Chem 5 (2005) 751-762
33. Hajduk P.J. SAR by NMR: putting the pieces together. Mol Interv 6 (2006) 266-272
34. Babaoglu K., Shoichet, and Brian B.K. Deconstructing fragment-based inhibitor discovery. Nat Chem Biol 2 (2006) 720-723
35. Wilson R.M., and Danishefsky S.J. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J Org Chem 71 (2006) 8329-8351
36. Arai H., Beierle K., Fullenwider C., Kai Z., and Rishton G.M. Chemically conditioned extracts of ginger oil: Leadlike 'alkaloidal' compounds derived from natural extracts via reductive amination. Abstracts, 40th Western Regional Meeting of the American Chemical Society. Anaheim, CA, United States, January 22-25 (2006) WRM-351
37. Aronov A.M., and Bemis G.W. A minimalist approach to fragment-based ligand design using common rings and linkers: Application to kinase inhibitors. Proteins: Struct, Funct Bioinform 57 (2004) 36-50
38. Vassiliou S., Yiotakis A., and Magriotis P.A. Efficient enantioselective synthesis of orthogonally protected (R)-α-alkylserines compatible with the solid phase peptide synthesis. Tetrahedron Lett 47 (2006) 7339-7341
39. Hartwig W., and Mittendorf J. Enantioselective synthesis of 2,3-diamino acids by the bislactim ether method. Synthesis 11 (1991) 939-941
40. Kedrowski B.L. Synthesis of orthogonally protected (R)- and (S)-2-methylcysteine via an enzymatic desymmeterization and curtius rearrangement. J Org Chem 68 (2003) 5403-5406
41. Andersson M.A., Epple R., Fokin V.V., and Sharpless K.B. A new approach to osmium-catalyzed asymmetric dihydroxylation and aminohydroxylation of olefins. Agnew Chem Int Ed 41 (2002) 472-475
42. Cogan D.A., and Ellman J.A. Asymmetric synthesis of the α,α-dibranched amines by the trimethylaluminum-mediated 1,2-addition of organolithiums to tert-butanesulfinyl ketimines. J Am Chem Soc 121 (1999) 268-269
43. Domling A. Recent developments in isocyanide based multicomponent reactions in applied chemistry. Chem Rev 106 (2006) 17-89
44. Tempest P.A. Recent advances in heterocycle generation using the efficient Ugi multiple-component condensation reaction. Curr Opin Drug Discov Dev 8 (2005) 776-788
45. Hulme C., and Gore V. Multi-component reactions: emerging chemistry in drug discovery from xylocain to crixivan. Curr Med Chem 10 (2003) 51-80
46. Yamada T., Ichino T., Hanyu M., Ninomiya D., Yanagihara R., Miyazawa T., and Murashima T. A novel intramolecular hydrogen bonding between a side-chain pyridine ring and an amide hydrogen of the peptide backbone in tripeptides containing the new amino acid, α,α-di(2-pyridyl)glycine. Org Biomol Chem 2 (2004) 2335-2339
47. Kaldor S.W., Siegel M.G., Fritz J.E., Dressman B.A., and Hahn P.J. Use of solid supported nucleophiles and electrophiles for the purification of non-peptide small molecule libraries. Tetrahedron Lett 37 (1996) 7193-7196
48. Booth R.J., and Hodges J.C. Polymer-supported quenching reagents for parallel purification. J Am Chem Soc 119 (1997) 4882-4886
49. Cork D., and Hird N. Work-up strategies for high-throughput solution synthesis. Drug Discov Today 7 (2002) 56-63